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Introduction
Triggering receptor expressed on myeloid cells 2 (TREM2) is 
a cell-surface receptor of the Ig superfamily that is found in 
microglia, osteoclasts, and other tissue macrophages in vivo 
(1–3) as well as in monocyte-derived DCs (4), bone marrow–
derived macrophages, and macrophage cell lines in vitro (5). 
TREM2 binds polyanions, such as dextran sulphate, bacterial 
lipooligosaccharides, and various phospholipids (6–8). It trans-
mits intracellular signals through an associated transmembrane 
adapter, DAP12, which contains tyrosine-based activation 
motifs (ITAMs) in its cytoplasmic domain (9). DAP12 ITAMs 
recruit the protein tyrosine kinase Syk, which mediates the 
phosphorylation of PLC-γ, PI3K, Vav2/3, and other downstream 
molecules that trigger cell activation (10). Besides directly trig-
gering tyrosine phosphorylation, the TREM2/DAP12 complex 
cooperates with CSF-1 receptor (CSF-1R) signaling (11), while it 
interferes with TLR signaling (12–14).
Individuals homozygous for rare inactivating mutations in 
either TREM2 or TYROBP, which encodes DAP12, develop a 
lethal form of progressive, early onset dementia known as Nasu-
Hakola disease (NHD) (1). Patients with NHD are asymptom-
atic through early adulthood, present with neuropsychiatric 
symptoms in their third and fourth decades, and expire between 
the ages of 35 and 45 (15). Postmortem analysis of these rare 
patients has revealed massive gliosis, with pathology predomi-
nantly of the subcortical white matter that includes common 
demyelinating lesions (15).
While generation of myelin depends primarily on oligoden-
drocytes (ODCs) (16), microglia contribute to myelination by 
removing damaged myelin sheaths and releasing soluble factors 
that promote differentiation of ODCs and subsequent remyelin-
ation (17–19). Thus, the association between TREM2 deficiency 
and demyelinating NHD suggests that microglia may require 
TREM2 for removing damaged myelin and supporting myelin 
regeneration by ODCs. While DAP12-deficient mice showed 
thalamic hypomyelinosis with synaptic degeneration (20), the 
function of TREM2 in myelination remains to be directly investi-
gated. An in vitro study found that reduced expression of TREM2 
in a microglia cell line impaired phagocytosis of apoptotic neu-
rons (21). Moreover, an in vivo study showed that intravenous 
injection of bone marrow–derived myeloid cells overexpressing 
TREM2 during experimental autoimmune encephalomyelitis, a 
model of immune-mediated demyelination, curbed disease by 
promoting the clearance of apoptotic neurons and secretion of 
IL-10 (22). However, this model may not recapitulate the func-
tion of bona fide microglia, either in normal myelination or 
nonautoimmune demyelinating diseases, such as NHD. In fact, 
microglia are brain-resident cells that populate the brain during 
embryogenesis and self renew throughout life (23–25), whereas 
adoptively transferred myeloid cells reach the CNS only when 
inflammation disrupts the blood-brain barrier (26).
Here, we addressed the impact of TREM2 deficiency on 
brain-resident microglia in vivo during aging and in a model of 
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whether TREM2 deficiency increases susceptibility to induced 
demyelination. To address this question, we chose to study the 
cuprizone model of demyelination, in which cuprizone expo-
sure induces apoptosis of mature ODCs, demyelination in the 
CNS, recruitment of astrocytes, and activation of brain-resident 
microglia without damaging the blood-brain barrier (27, 28). In 
this model, there is no confounding infiltration of bone mar-
row–derived myeloid cells (26, 32). WT and Trem2–/– mice were 
fed a diet containing 0.2% cuprizone. Mice were analyzed at 4 
weeks, the peak of demyelination, or at 12 weeks, at which point 
both demyelination and remyelination occur. Some groups of 
mice were fed a normal diet for 2 additional weeks after 4 or 12 
weeks of cuprizone treatment to allow myelin recovery. We ana-
lyzed myelination of untreated, cuprizone-treated, and recover-
ing mice by transmission electron microscopy (TEM) of the cor-
pus callosum, a sensitive target of demyelination. To precisely 
quantify the extent of demyelination and remyelination, we 
measured the ratio of axon circumference to myelin circumfer-
ence (G ratio). Before cuprizone exposure, the corpus callosum 
of Trem2−/− mice was myelinated to the same extent as that in 
the WT mice (Figure 2, A–C). After 4 weeks of cuprizone treat-
ment, WT mice showed clear demyelination, with axonal swell-
ing, increased G ratio, and accumulation of myelin debris (Fig-
ure 2, A–C). Myelination returned to normal after 2 weeks of a 
cuprizone-free diet (Supplemental Figure 1; supplemental mate-
rial available online with this article; doi:10.1172/JCI77983DS1). 
Like WT mice, Trem2–/– mice showed a clear demyelination at 
4 weeks (Figure 2, A–C), which was repaired after 2 weeks of a 
cuprizone-free diet (Supplemental Figure 1). After 12 weeks of 
cuprizone treatment, WT mice showed partial demyelination, 
suggesting ongoing remyelination, which became complete after 
2 weeks of a cuprizone-free diet (Figure 2, A–C). In contrast, the 
corpus callosum of Trem2–/– mice remained largely demyelinat-
ed and showed abundant accumulation of myelin debris, which 
persisted even after the 2-week recovery period (Figure 2, A–C). 
Trem2–/– mice showed clear axonal dystrophy, as evinced by the 
presence of axonal spheroids and increased G ratio throughout 
the experiment (Figure 2C). These data indicate that TREM2 
deficiency has no impact on the initial demyelination, but does 
affect subsequent remyelination when the cuprizone treatment 
is prolonged, most likely by impairing myelin removal as well as 
myelin regeneration.
To corroborate these results, we performed immunohisto-
logical analysis of myelin basic protein (MBP), a major compo-
nent of myelin. WT mice showed an initial reduction of MBP 
staining after 4 weeks of cuprizone treatment, followed by a 
sharp reduction after 12 weeks and a reconstitution of a nor-
mal MBP staining in the recovery phase (Figure 2, D and E). 
We interpret the MBP reduction at 4 weeks to reflect apoptosis 
of myelinating ODCs, whereas the sharp MBP reduction at 12 
weeks was probably due to the removal of damaged myelin. In 
Trem2–/– mice, MBP staining also appeared reduced at 4 weeks to 
levels similar to those of WT, but unlike in WT mice, the sharp 
reduction in MBP staining was not apparent at 12 weeks and 
MBP continued to be reduced after 2 weeks of recovery. These 
data corroborate that TREM2 deficiency results in impaired 
clearance of damaged myelin after prolonged demyelination, 
nonautoimmune demyelination, the cuprizone model, which is 
characterized by apoptosis of mature ODCs, followed by recruit-
ment of astrocytes and activation of brain-resident microglia 
to remove myelin debris (27, 28). We found that total numbers 
and density of microglia increased with age in various regions of 
the brain in WT mice, as previously reported (29–31), whereas 
age-matched Trem2–/– mice had fewer microglia. After cuprizone 
challenge, Trem2–/– microglia failed to activate transcriptional 
programs that promote myelin removal and repair, such as lipid/
fatty acid capture, transport, and metabolism, as well as those 
encoding chemoattractants, inflammatory mediators, and tro-
phic factors for ODCs. Impaired microglial activation was asso-
ciated with prolonged microgliosis, likely stimulated by persis-
tence of myelin debris, as well as impaired repopulation of OCDs 
and subsequent remyelination. Moreover, a TREM2 reporter 
assay showed that TREM2 detects lipidic components of myelin, 
suggesting that TREM2 directly senses myelin damage. We pos-
tulate that TREM2 is a lipid sensor that is essential to promoting 
microglial activation in response to insults to the white matter.
Results
TREM2 deficiency affects microglial numbers during aging. NHD 
becomes clinically apparent in presenile individuals, and the 
underlying pathological changes are recorded postmortem. 
However, it is not known at which point in life TREM2 deficiency 
begins to affect microglia and myelination. To address this ques-
tion, we stained brain sections of 6-month-old, 1-year-old, and 
2-year-old WT and Trem2–/– mice for ionized calcium-binding 
adapter molecule 1 (Iba-1), which is a marker commonly used 
to identify microglia in the CNS. WT mice had a progressive 
increase in microglia over time, which was highly significant in 
the white matter, particularly in the corpus callosum (P < 0.0001) 
and the cerebellum (P < 0.01), but not in the cerebral cortex 
(Figure 1, A and B). Although Trem2–/– mice showed microglial 
numbers similar to WT mice at 6 months, no obvious increase 
occurred over time. In fact, microglia were significantly less 
abundant in 2-year-old Trem2–/– mice than in age-matched WT 
mice, especially in the corpus callosum, cerebellum, and hippo-
campus (P < 0.0001, P < 0.01, P < 0.05) (Figure 1, A and B). Addi-
tionally, microglia in 2-year-old Trem2–/– mice showed dystrophic 
morphology characterized by smaller cell body and reduced 
ramifications (Figure 1B, insets, and Figure 1C). Measurement of 
Iba-1+ areas confirmed a progressive shrinking of the cell body 
of TREM2-deficient microglia (Figure 1D). Thus, TREM2 defi-
ciency affects long-term numbers and morphology of microglia. 
These results are reminiscent of those we previously reported 
for microglia in 1-year-old Dap12–/– mice, which are present in 
lower numbers and have abnormal morphology compared with 
WT mice (11). Despite microglial defects, TREM2 deficiency was 
not associated with marked demyelination, neuronal loss, other 
marked histological changes, or obvious behavioral abnormali-
ties in aged mice (data not shown), suggesting that a deficit of 
TREM2 in mouse is not sufficient to cause pathological changes 
equivalent to human NHD.
TREM2 is required for myelin debris removal and remyelination 
after cuprizone-induced demyelination. As Trem2–/– mice did not 
develop spontaneous demyelination, we wanted to determine 
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been reported in CNS cells other than microglia (33, 34), recent-
ly published studies demonstrated that Trem2 is specifically 
expressed in microglia — but not other cells in the CNS — under 
steady-state conditions (35–37). Moreover, we found that Trem2 
was not expressed in astrocytes or ODC precursors after 4 weeks 
of cuprizone feeding, while its expression in microglia was elevat-
ed (Supplemental Figure 2). These data indicate that impact of 
TREM2 on remyelination is largely through microglia.
To investigate the microglial response to cuprizone-induced 
demyelination, we stained brain sections for Iba-1 and deter-
mined the frequency of Iba-1+ cells. Consistent with previous 
reports (38), WT mice showed a peak of microgliosis at 4 weeks 
which hinders subsequent myelin regeneration. This conclu-
sion was supported by immunohistochemical analysis of ODC. 
WT mice showed a limited reduction of ODCs after 4 and 12 
weeks of cuprizone treatment, which stabilized during recov-
ery, whereas Trem2–/– mice showed a progressive and signifi-
cant ODC reduction during cuprizone treatment and recovery 
(Figure 2, F and G). We conclude that prolonged treatment of 
Trem2–/– mice with cuprizone causes a persistent demyelination 
that mimics that observed in NHD.
Trem2–/– mice show dystrophic microgliosis in response to demy-
elination. We next sought to define the mechanism of defective 
remyelination in Trem2–/– mice. Although TREM2 expression has 
Figure 1. Trem2 deficiency affects aging-dependent expansion of microglia. (A) Microglial numbers were counted as Iba-1+ cells per high-power field (HPF) 
in the corpus callosum, cerebellum, hippocampus, and cortex in mice at 6 months, 1 year, and 2 years after birth. Brain regions analyzed are shown in the 
corresponding drawings. (B) Representative images of Iba-1+ cells in WT and Trem2–/– mice at different ages. cc, corpus callosum. (C and D) Steady-state 
microglia in aged Trem2–/– mice show deramified morphology compared with microglia of age-matched WT mice. (C) Representative images of Iba-1+ cells 
in 2-year-old WT and Trem2–/– mice. (D) Quantification of microglial surface area (in μm2) visualized by Iba-1 staining. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; 
****P ≤ 0.0001, 2-way ANOVA. Original magnification, ×20 (B); ×60 (B, insets; C). Scale bars: 100 μm (B); 30 μm (B, insets; C). Data represent 5 to 10 mice 
(A and B) and 4 mice (C and D) for each group from a total of 2 experiments. An average of 10 HPF per mouse were evaluated in A. An average of 50 cells in 
10 HPF per mouse were evaluated in D. Error bars represent mean ± SEM.
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as indicated by smaller cell bodies, as well as fragmentation, 
beading, and reduced ramification of microglial processes (Fig-
ure 3, C and D). These morphological changes suggested that 
Trem2–/– microglia are dysfunctional.
TREM2 is required to activate microglial transcriptional pro-
grams for myelin clearance and repair. To further determine the 
impact of TREM2 deficiency on the microglial response to demy-
elination, we performed gene-expression profiling on microglia 
of cuprizone treatment, which progressively declined at 12 
weeks and returned back to basal levels after recovery (Figure 
3, A and B). In Trem2–/– mice, microgliosis was less vigorous at 
4 weeks, but persisted throughout the recovery phase (Figure 3, 
A and B). This unresolved microgliosis may be the consequence 
of a persisting accumulation of myelin debris. As previously 
observed in nontreated mice (see Figure 1), Trem2–/– microglia in 
cuprizone-treated mice also exhibited dystrophic morphology, 
Figure 2. Trem2–/– mice show impaired remyelination after cuprizone treatment. Mice were fed regular chow (control) or 0.2% cuprizone diet for 4 weeks, 12 
weeks, or 12 weeks followed by 2 weeks of regular chow (recovery). (A–C) Myelination was assessed by TEM. (A) Strategy used for corpus callosum sectioning 
is indicated in red. (B) Representative images of corpus callosum in different treatments. Deposition of myelin debris (red arrowheads) and axonal spheroids 
(white arrowheads) is indicated in Trem2–/– mice. (C) Demyelination and remyelination after cuprizone feeding is measured by changes in G ratios. (D–G) 
Brain sections were stained for MBP and Olig-2 to detect myelin and ODCs, respectively. Representative images for MBP (D) and Olig-2 staining (F). Percent-
age reduction of MBP reactivity in the total white matter area (E) and frequencies of Olig-2+ cells (G). *P ≤ 0.05; ***P ≤ 0.001; ****P ≤ 0.0001, 2-way ANOVA. 
Original magnification, ×6000 (B); ×4 (D); ×20 (F). Scale bars: 5 μm (B); 500 μm (D); 100 μm (F). Data represent 2 to 3 mice (B and C) and 3 to 8 mice (D–G) per 
group. An average of 10 HPF per mouse were evaluated. Error bars represent mean ± SEM.
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the induced genes persist and are further increased through-
out cuprizone treatment, others are downregulated at late time 
points correlating with the ensuing remyelination.
To assess the impact of TREM2 deficiency on the cupri-
zone-induced transcriptional activation program, we visualized 
the gene signatures across the entire data set (WT and Trem2–/– 
microglia). While most transcripts that were downregulated after 
cuprizone were not greatly affected by TREM2 deficiency, we 
noticed that many transcripts that were selectively increased at 
either 4 weeks, 12 weeks, or both 4 and 12 weeks were impaired in 
Trem2–/– mice (Figure 4C). These included Axl, encoding a phago-
cytic receptor important for the uptake of myelin debris (39); 
Apoe, Apoc1, Lpl, and Ch25h, which specify key molecules for lipid 
transport and metabolism; and Igf1, which is a crucial growth fac-
tor for ODC differentiation. We also noticed that a group of tran-
scripts that specifically upregulated at 12 weeks were affected by 
TREM2 deficiency. These encoded several inflammatory genes, 
such as Il1b, Ifnb1, Il6, and Il12b. Some of these transcriptional 
changes were further validated by quantitative PCR (qPCR) 
(Figure 4D). Together, these data indicate that during cuprizone-
induced demyelination, TREM2 is required to activate microglia, 
prompting their response to myelin products and the induction of 
genes involved in myelin removal and repair and ODC matura-
tion as well as inflammatory responses.
isolated from brains of WT and Trem2–/– mice that were either 
untreated (controls) or treated with cuprizone for 4 weeks (peak 
demyelination) or 12 weeks (prolonged demyelination and par-
tial remyelination). A scatter plot of WT and Trem2–/– microglia 
isolated from control mice demonstrated similar transcriptional 
profiles between the 2 genotypes, suggesting that TREM2 defi-
ciency does not have a substantial impact on microglia in steady 
state (Figure 4A). We next determined the impact of cuprizone 
treatment on microglial gene transcription during the different 
stages of demyelination by comparing gene expression among 
WT mice. We found that a large set of microglial transcripts 
were upregulated (≥2-fold) at 4 weeks (Figure 4B); some of 
these transcripts remained elevated or were further upregulated 
at 12 weeks, whereas others were downregulated or returned to 
baseline at 12 weeks (Figure 4C). An additional set of transcripts 
were upregulated de novo at 12 weeks (Figure 4C). We further 
noticed that many genes had reduced expression at 12 weeks 
(Figure 4B). These transcripts included some that were initial-
ly upregulated at 4 weeks as well as others that were progres-
sively reduced from the beginning of the treatment, but reached 
a marked downregulation (≤2-fold) only at 12 weeks (Figure 
4C). Collectively, these data suggest that cuprizone treatment 
in WT mice activates a microglial transcriptional program ear-
ly on, during the acute phase of demyelination. While some of 
Figure 3. Trem2 deficiency impairs microglial response to demyelination. Corpus callosum sections were stained with Iba-1 to detect microgliosis. (A) 
Representative images of Iba-1 staining. (B) Iba-1+ microglial frequencies per HPF. (C and D) Microglial morphology after cuprizone treatment. (C) Morpho-
logical assessment of WT and Trem2–/– microglia after 12 weeks of cuprizone treatment. Fragmentation, beading (arrowheads), and spheroid formation 
(asterisks) are indicated. (D) Surface area of Iba-1+ microglia is quantified. **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001, 2-way ANOVA. Original magnification, 
×20 (A); ×60 (A, insets; C, middle and bottom images); and ×40 (C, top images). Scale bars: 100 μm (A); 30 μm (C, middle and bottom images); 50 μm (C, 
top images). Data represent 3 to 8 mice (B) and 4 mice per group (D) for a total of 2 experiments. An average of 10 HPF per mouse were evaluated for B. An 
average of 50 cells in 10 HPF per mouse were evaluated for D. Error bars represent mean ± SEM.
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TREM2 detects lipid components of myelin. We next sought 
to determine the potential ligands that may activate TREM2 
during demyelination. For this, we expressed mouse TREM2 
(mTREM2) and DAP12 in a reporter cell line transfected with 
a chimeric gene encoding the GFP under the control of nuclear 
factor of activated T cells–responsive (NFAT-responsive) ele-
ments. Engagement of the mTREM2/DAP12 complex in these 
cells leads to mobilization of intracellular Ca2+, which triggers 
GFP expression. Since TREM2 was shown to detect polyan-
ions and phospholipids (6, 8), we tested lipid components of 
myelin. We initially incubated mTREM2-DAP12 reporter cells 
in wells coated with crude lipid extracts obtained from normal 
mouse brains. Myelin lipids induced GFP expression, which was 
blocked by the addition of anti-TREM2 mAb (Figure 5, A and 
B). Control mTREM1-DAP12 reporter cells or parental reporter 
cells were not activated. Thus, myelin components can trig-
ger TREM2 signaling. To further investigate the specificity of 
TREM2, we incubated mTREM2-DAP12 reporter cells with puri-
fied lipid components of myelin, such as sulfatide, cerebroside, 
sphingomyelin, and various phospholipids. Many of these lipidic 
components stimulated TREM2 signaling, with the exception 
of cerebroside (Figure 5C). These results suggest that TREM2 
may detect myelin injury by sensing some of the glycolipids and 
phospholipids that compose myelin and may be exposed during 
myelin damage.
Discussion
It has been established that TREM2 is expressed in brain-res-
ident microglia (1, 2, 35) and that TREM2 deficiency causes 
demyelinating NHD (1). However, the function of TREM2 in 
brain-resident microglia in vivo and the mechanisms underly-
ing NHD demyelination are poorly understood. Our study dem-
onstrates that TREM2 is a sensor for brain lipidic components 
that promotes microglial fitness and expansion during normal 
aging. Indeed, TREM2 deficiency hindered the accumulation 
of microglia during aging, particularly in the corpus callosum, 
which is rich in myelin that may provide a major stimulus for 
TREM2 signaling. Microglia were also defective in the cerebel-
lum and hippocampus, which contain less myelin than the cor-
pus callosum; however, no defect was observed in the cortex. 
The variable impact of TREM2 signaling in distinct brain regions 
may depend on their myelin content, the presence of alterna-
tive TREM2 ligands, the level of TREM2 expression, and the 
presence of other receptor-ligand interactions that can com-
Figure 4. Trem2–/– microglia fail to upregulate transcripts implicated in activation, phagocytosis, and lipid metabolism in response to demyelination. 
Gene expression analyses of FACS-sorted WT and Trem2–/– microglia from control mice and mice fed with cuprizone diet for 4 or 12 weeks. (A) Scatter 
plot shows comparison of WT and Trem2–/– microglial transcriptomes in steady state. Numbers indicate transcripts that are differentially expressed (fold 
change ≥ 2) between WT and Trem2–/– microglia. The Trem2 transcript is indicated. (B) Transcriptional changes of WT microglia in response to cuprizone 
feeding for 4 weeks or 12 weeks compared with control (fold change ≥ 2 and ≤ 2). Numbers represent transcripts that are either differentially regulated at 
4 weeks, 12 weeks, or both 4 and 12 weeks. (C) Heat map shows the expression of cuprizone-induced genes from B in WT and Trem2–/– microglia. Selected 
transcripts are indicated. (D) Selected transcriptional changes (from C) were further validated by qPCR.
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pensate for the lack of TREM2. Interestingly, while the reduc-
tion of microglia in Trem2 –/– mice was not paralleled by obvious 
pathology, a complete defect in TREM2 function appears suffi-
cient to cause NHD in humans. Since the mTREM gene complex 
contains more genes than its human counterpart (10), it is pos-
sible that TREM2 deficiency in mice is partially compensated by 
other as-yet-uncharacterized TREM receptors. Alternatively, the 
development of NHD may require not only a genetically inher-
ited TREM2 deficiency, but also environmental stimuli that do 
not occur in mice in the steady state.
We used the cuprizone model to expose a potential func-
tion for TREM2 during demyelination in mice. In this model, 
which predominantly affects the corpus callosum, TREM2 was 
required for microglial response to prolonged demyelination and 
induction of coordinated transcriptional programs for removal 
of damaged myelin sheaths and secretion of trophic factors that 
support ODC differentiation/survival. A defect in TREM2 func-
tion resulted in accumulation of myelin debris, which has been 
shown to inhibit ODC precursor cell differentiation and remy-
elination (40). Moreover, accumulating myelin debris may pro-
vide continued recruitment signals to microglia, which would 
explain the maintenance of microglial numbers in the corpus cal-
losum of Trem2–/– mice throughout cuprizone treatment, includ-
ing the recovery phase.
We showed that TREM2 signaling sustains multiple 
microglial transcriptional programs that do not fit the conven-
tional M1/M2 paradigm (41). One of these programs leads to 
the expression of genes induced by IFN-α/β and inflamma-
tory cytokines, consistent with previous reports (42, 43). Most 
likely, myelin degradation products enter the microglia and 
engage innate sensors of damage-associated molecular pat-
terns, which trigger the IFN-α/β, NF-κB, and inflammasome 
pathways. Another transcriptional program promotes lipid and 
cholesterol uptake, transport, and processing. The expression 
of genes for lipid processing is consistent with previous studies 
(44, 45) and is most likely a consequence of microglia uptake of 
lipoproteins released during myelin damage. Finally, activated 
microglia express genes that encode chemokines that attract 
other glial cells and trophic factors, such as IGF1, that promote 
differentiation and maturation of ODCs, which in turn mediate 
remyelination. How TREM2 mediates the induction of these 
multiple gene programs remains unclear. Given that TREM2 
and DAP12 promote macrophage survival in the presence of 
limited concentrations of CSF-1 (11, 46) and that CSF-1 pro-
duction in the brain may be limited, especially during neuro-
nal and glial damage, TREM2-deficient microglia may be unfit 
overall and hence dysfunctional; they simply may not be suf-
ficiently robust to activate the multiple programs required for 
an effective response to myelin damage. Alternatively, TREM2 
may be required as a coreceptor for other activating receptors. 
As DAP12 is located in lipid rafts, engagement of TREM2 may 
induce aggregation and mobilization of multiple receptors to 
lipid rafts (47), thereby facilitating their clustering and activa-
tion of multiple signaling pathways.
Very recent studies have shown that individuals hetero-
zygous for a rare variant of TREM2, R47H, have high risk for 
developing Alzheimer disease (AD) (34, 48, 49). The same vari-
ant is a risk factor for Parkinson’s disease (PD) and sporadic 
amyotrophic lateral sclerosis (ALS) (50, 51). The R47H variant 
impairs TREM2 lipid recognition (52). Thus, it is possible that 
the TREM2-dependent mechanisms underlying demyelination, 
AD, PD, and ALS are similar. We have shown that TREM2-
deficient microglia fail to remove damaged myelin; similarly, 
TREM2 may be required for an effective microglia response to 
and clearance of β-amyloid plaques and other aggregated prion-
like proteins. TREM2 may also be required to sustain microglial 
trophic function, which has been shown to contribute to neu-
ronal homeostasis in the aging brain (37). Interestingly, it was 
reported that microglial TREM2 expression is reduced in aged 
mice (37). It is possible that a progressive decline in TREM2 
Figure 5. Myelin lipids activate mTREM2-NFAT-GFP reporter cells. (A and B) mTREM1, mTREM2, and parental reporter cells were stimulated with crude 
myelin lipids purified from brains of WT mice with or without the addition of anti-mTREM2 mAb. (A) Representative data show GFP expression examined 
by flow cytometry 16 hours after stimulation. (B) Results from 3 independent experiments are quantified. Ctl, control. (C) mTREM2 reporter cells were 
stimulated overnight with various lipids at indicated concentrations, and GFP expression was measured by flow cytometry. Data are representative of 2 
independent experiments. Error bars represent mean ± SEM.
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dehydrated in graded alcohol solutions and propylene, embedded in 
Epon, and examined by light microscopy after toluidine blue staining. 
Thin sections cut onto Formvar-coated slot grids and stained with ura-
nyl acetate and lead citrate were examined and recorded with a JEOL 
1200 electron microscope. G ratios were determined by measuring 
the ratio of circumference of axon over myelin using ImageJ (http://
imagej.nih.gov/ij/).
Gene expression analysis and qPCR. Brains from 3 mice were 
dissected and dissociated using a neuronal tissue dissociation kit 
(Miltenyi Biotec). Microglia were enriched using mouse CD45 
beads (Miltenyi Biotec) followed by FACS sorting of CD45loCD11b+ 
cells using CD45-eFluor450 (30F-11, eBioscience) and CD11b-APC 
(M1/70, BD Biosciences — Pharmingen). Astrocytes and ODC pro-
genitors were FACS sorted from the CD45– fraction using ASCA-1– 
PE antibody (ASCA-1) and A2B5-APC antibody (105HB29), respec-
tively (Miltenyi Biotec). A FACSAria II (BD) was used for all FACS-
sorting experiments, with greater than 99% purity achieved. Cells 
were sorted directly into RLT buffer, and RNA was extracted using 
an RNeasy Micro Kit (QIAGEN). For microarray analyses, hybrid-
ization (Affymetrix MoGene 1.0 ST array) and data processing were 
performed at the Washington University Genome Center. Robust 
multi-array average (RMA) normalization was used, and genes were 
prefiltered for expression value of 120 or more. Scatter plots and 
dot plots were produced using the Multiplot module of GenePattern 
(Broad Institute). Venn diagrams and heat map were generated from 
a selected gene list using GENE-E (Broad Institute). The expression 
of selected gene list was further validated by qPCR using a SYBR 
Green PCR Master Mix (Bio-Rad) and amplified on an ABI7000 
machine (Applied Biosystems). qPCR primers used in this study are 
listed in Supplemental Table 1.
Accession numbers. All original microarray data were deposited in 
the NCBI’s Gene Expression Omnibus (GEO GSE66926).
Reporter assay. 43.1 reporter T cells (56) were stably transfected 
with mTREM2 or mTREM1 and DAP12 cDNAs. A monoclonal anti-
murine TREM2 antibody (13) was used to block TREM2 signaling. 
To extract myelin lipids, myelin vesicles were generated as previous-
ly described (57). Briefly, brain from a WT mouse was homogenized 
with a Dounce homogenizer and resuspended in 0.25 M sucrose 
solution, followed by centrifugation onto a sucrose gradient. Crude 
lipids were extracted from myelin vesicles with methanol. Myelin 
lipids or other purified lipids dissolved in methanol were coated 
onto a high-absorbent plate (catalog 442404, Thermo Scientific) 
and incubated at room temperature for 4 hours to allow methanol 
evaporation. Reporter cells were added to lipid-coated wells or sol-
vent-treated control wells and assessed after overnight incubation. 
Reporter activity (%) was defined as percentage of GFP+ cells in 
lipid-coated wells subtracted from background (percentage of GFP+ 
cells in solvent-treated wells).
Statistics. Data in figures are presented as mean ± SEM. All sta-
tistical analysis was performed using Prism (GraphPad). Statistical 
analysis to compare the mean values for multiple groups was per-
formed using 1-way or 2-way ANOVA with correction for multiple 
comparisons. Comparison of 2 groups was performed using a 2-tailed 
unpaired t test (Mann Whitney U test). Values were accepted as sig-
nificant at P ≤ 0.05.
Study approval. All animal studies were approved by the Washing-
ton University Animal Studies Committee.
expression may also occur during aging in certain areas of the 
human brain, curtailing microglial numbers and the microglial 
response to the breakdown of myelin, glial cells, and neurons, 
which would create fertile ground for neurodegeneration. It will 
be essential to quantify TREM2 expression in different areas of 
the mouse and human brain at different ages in future studies.
Our TREM2 reporter assays suggest that mTREM2 may 
bind a broad array of glycolipids and phospholipids, which may 
be exposed on damaged myelin sheaths as well as on dying 
glial cells and neurons. We recently demonstrated that human 
TREM2 detects a similarly broad range of anionic and zwitter-
ionic lipid ligands (52). However, because cerebroside did not 
activate mTREM2 signaling, TREM2 ligands may have distinct 
structural constraints that remain to be defined. It is also unclear 
whether TREM2 binds lipid components within lipoproteins, 
exosomes, apoptotic cells, or other supramolecular structures. 
Recent studies have demonstrated that TREM2 is released 
from the surface of cells through the consecutive action of 
ADAM10 and γ-secretase (53, 54). Thus, soluble TREM2 might 
also contribute to transport, delivery, or metabolism of myelin 
products. In conclusion, our data demonstrate that TREM2 is a 
lipid sensor that transmits intracellular signals that promote the 
overall fitness of microglia during aging as well as their ability 
to respond to prolonged demyelination. The cuprizone treat-
ment of Trem2–/– mice presented here partially recapitulates the 
pathology of human NHD. Future studies will determine wheth-
er impairment of TREM2 function affects other demyelinating 
and neurodegenerative diseases.
Methods
Mice and cuprizone treatment. Generation of Trem2–/– mice has been 
previously described (13). All mice were bred and housed in the same 
animal facility. Cuprizone was purchased from Sigma-Aldrich (catalog 
14690) and sent to Harlan Laboratories to produce a diet containing 
0.2% cuprizone.
Immunohistochemistry. Paraffin-embedded brain sections (2 
μm thick) were dewaxed, rehydrated, and treated with 0.3% H2O2/
methanol to block endogenous peroxidase. Heat-induced antigen 
retrieval was obtained by microwave treatment or incubation in a 
thermostatic bath using 1 mM EDTA-Tris-HCl buffer, pH 8.0. Sec-
tions were stained with rat anti-MBP mAb (clone AB980, Chemi-
con), rabbit anti–Iba-1 polyclonal antibody (Wako Chemicals, cata-
log 019-19741), and rabbit anti–Olig-2 polyclonal antibody (Life 
Technologies, catalog P21954). Stainings were revealed by Real 
EnVision Rabbit HRP Labelled Polymer System (Dako) and Rat on 
Mouse HRP Polymer Kit (Biocare Medical) using 3,3′-diaminoben-
zidine tetrahydrochloride (0.05%) as a chromogen and hematoxylin 
as counterstaining. Demyelination was evaluated with a morpho-
metric method by measuring the percentage of demyelinated area 
over the total area of corpus callosum. A Nikon Eclipse 50i micro-
scope was used to count cells. Changes in MBP and microglia sur-
face areas were measured by an Olympus DP70 camera mounted on 
an Olympus Bx60 microscope, using CellF Imaging software (Soft 
Imaging System GmbH).
TEM. TEM was performed as previously described (55). In brief, 
brains were perfused with formalin and fixed in formalin overnight. 
Dissected tissues (1 mm in thickness) were postfixed in buffered OsO4, 
Downloaded from http://www.jci.org on October  9, 2015.   http://dx.doi.org/10.1172/JCI77983
The Journal of Clinical Investigation   R e s e a R c h  a R t i c l e
2 1 6 9jci.org   Volume 125   Number 5   May 2015
 1. Paloneva J, et al. Mutations in two genes encod-
ing different subunits of a receptor signaling 
complex result in an identical disease phenotype. 
Am J Hum Genet. 2002;71(3):656–662.
 2. Schmid CD, et al. Heterogeneous expression of 
the triggering receptor expressed on myeloid 
cells-2 on adult murine microglia. J Neurochem. 
2002;83(6):1309–1320.
 3. Correale C, et al. Bacterial sensor triggering 
receptor expressed on myeloid cells-2 regulates 
the mucosal inflammatory response. Gastroenter-
ology. 2013;144(2):346–356 e343.
 4. Bouchon A, Hernandez-Munain C, Cella M, Col-
onna M. A DAP12-mediated pathway regulates 
expression of CC chemokine receptor 7 and 
maturation of human dendritic cells. J Exp Med. 
2001;194(8):1111–1122.
 5. Daws MR, Lanier LL, Seaman WE, Ryan JC. 
Cloning and characterization of a novel mouse 
myeloid DAP12-associated receptor family. Eur J 
Immunol. 2001;31(3):783–791.
 6. Daws MR, Sullam PM, Niemi EC, Chen TT, 
Tchao NK, Seaman WE. Pattern recognition by 
TREM-2: binding of anionic ligands. J Immunol. 
2003;171(2):594–599.
 7. N’Diaye EN, et al. TREM-2 (triggering receptor 
expressed on myeloid cells 2) is a phagocytic recep-
tor for bacteria. J Cell Biol. 2009;184(2):215–223.
 8. Cannon JP, O’Driscoll M, Litman GW. Spe-
cific lipid recognition is a general feature of 
CD300 and TREM molecules. Immunogenetics. 
2012;64(1):39–47.
 9. Lanier LL. DAP10- and DAP12-associated 
receptors in innate immunity. Immunol Rev. 
2009;227(1):150–160.
 10. Ford JW, McVicar DW. TREM and TREM-like 
receptors in inflammation and disease. Curr Opin 
Immunol. 2009;21(1):38–46.
 11. Otero K, et al. Macrophage colony-stimulating 
factor induces the proliferation and survival of 
macrophages via a pathway involving DAP12 and 
beta-catenin. Nat Immunol. 2009;10(7):734–743.
 12. Peng Q, Long CL, Malhotra S, Humphrey MB. 
A physical interaction between the adaptor 
proteins DOK3 and DAP12 is required to inhibit 
lipopolysaccharide signaling in macrophages. Sci 
Signal. 2013;6(289):ra72.
 13. Turnbull IR, et al. Cutting edge: TREM-2 
attenuates macrophage activation. J Immunol. 
2006;177(6):3520–3524.
 14. Hamerman JA, Jarjoura JR, Humphrey MB, 
Nakamura MC, Seaman WE, Lanier LL. Cutting 
edge: inhibition of TLR and FcR responses in 
macrophages by triggering receptor expressed on 
myeloid cells (TREM)-2 and DAP12. J Immunol. 
2006;177(4):2051–2055.
 15. Verloes A, Maquet P, Sadzot B, Vivario M, Thiry 
A, Franck G. Nasu-Hakola syndrome: polycystic 
lipomembranous osteodysplasia with sclerosing 
leucoencephalopathy and presenile dementia.  
J Med Genet. 1997;34(9):753–757.
 16. Simons M, Lyons DA. Axonal selection and 
myelin sheath generation in the central nervous 
system. Curr Opin Cell Biol. 2013;25(4):512–519.
 17. Prinz M, Priller J, Sisodia SS, Ransohoff RM. 
Heterogeneity of CNS myeloid cells and their 
roles in neurodegeneration. Nat Neurosci. 
2011;14(10):1227–1235.
 18. Ransohoff RM, Cardona AE. The myeloid cells of 
the central nervous system parenchyma. Nature. 
2010;468(7321):253–262.
 19. Miron VE, et al. M2 microglia and macro-
phages drive oligodendrocyte differentiation 
during CNS remyelination. Nat Neurosci. 
2013;16(9):1211–1218.
 20. Kaifu T, et al. Osteopetrosis and thalamic hypo-
myelinosis with synaptic degeneration in DAP12-
deficient mice. J Clin Invest. 2003;111(3):323–332.
 21. Takahashi K, Rochford CD, Neumann H. Clear-
ance of apoptotic neurons without inflammation 
by microglial triggering receptor expressed on 
myeloid cells-2. J Exp Med. 2005;201(4):647–657.
 22. Takahashi K, Prinz M, Stagi M, Chechneva O, 
Neumann H. TREM2-transduced myeloid pre-
cursors mediate nervous tissue debris clearance 
and facilitate recovery in an animal model of 
multiple sclerosis. PLoS Med. 2007;4(4):e124.
 23. Greter M, Merad M. Regulation of microg-
lia development and homeostasis. Glia. 
2013;61(1):121–127.
 24. Gomez Perdiguero E, Schulz C, Geissmann F. 
Development and homeostasis of “resident” 
myeloid cells: the case of the microglia. Glia. 
2013;61(1):112–120.
 25. Ajami B, Bennett JL, Krieger C, Tetzlaff W, Rossi 
FM. Local self-renewal can sustain CNS microg-
lia maintenance and function throughout adult 
life. Nat Neurosci. 2007;10(12):1538–1543.
 26. Mildner A, et al. Microglia in the adult brain 
arise from Ly-6ChiCCR2+ monocytes only 
under defined host conditions. Nat Neurosci. 
2007;10(12):1544–1553.
 27. Matsushima GK, Morell P. The neurotoxicant, 
cuprizone, as a model to study demyelination 
and remyelination in the central nervous system. 
Brain Pathol. 2001;11(1):107–116.
 28. Gudi V, Gingele S, Skripuletz T, Stangel M. Glial 
response during cuprizone-induced de- and 
remyelination in the CNS: lessons learned. Front 
Cell Neurosci. 2014;8:73.
 29. Mouton PR, et al. Age and gender effects on 
microglia and astrocyte numbers in brains of 
mice. Brain Res. 2002;956(1):30–35.
 30. Tremblay ME, Zettel ML, Ison JR, Allen PD, 
Majewska AK. Effects of aging and sensory loss on 
glial cells in mouse visual and auditory cortices. 
Glia. 2012;60(4):541–558.
 31. Damani MR, Zhao L, Fontainhas AM, Amaral J, 
Fariss RN, Wong WT. Age-related alterations in 
the dynamic behavior of microglia. Aging Cell. 
2011;10(2):263–276.
 32. Kondo A, Nakano T, Suzuki K. Blood-brain bar-
rier permeability to horseradish peroxidase in 
twitcher and cuprizone-intoxicated mice. Brain 
Res. 1987;425(1):186–190.
 33. Sessa G, et al. Distribution and signaling of 
TREM2/DAP12, the receptor system mutated in 
human polycystic lipomembraneous osteodyspla-
sia with sclerosing leukoencephalopathy dementia. 
Eur J Neurosci. 2004;20(10):2617–2628.
 34. Guerreiro R, et al. TREM2 variants in Alzheimer’s 
disease. N Engl J Med. 2013;368(2):117–127.
 35. Butovsky O, et al. Identification of a unique TGF-β- 
dependent molecular and functional signature in 
microglia. Nat Neurosci. 2014;17(1):131–143.
 36. Jiang T, et al. Upregulation of TREM2 amelio-
rates neuropathology and rescues spatial cogni-
tive impairment in a transgenic mouse model of 
Alzheimer’s disease. Neuropsychopharmacology. 
2014;39(13):2949–2962.
 37. Hickman SE, et al. The microglial sensome 
revealed by direct RNA sequencing. Nat Neurosci. 
2013;16(12):1896–1905.
 38. Gudi V, et al. Spatial and temporal profiles of 
growth factor expression during CNS demyelin-
ation reveal the dynamics of repair priming. PLoS 
One. 2011;6(7):e22623.
 39. Hoehn HJ, Kress Y, Sohn A, Brosnan CF, Bourdon 
S, Shafit-Zagardo B. Axl–/– mice have delayed 
recovery and prolonged axonal damage following 
cuprizone toxicity. Brain Res. 2008;1240:1–11.
 40. Kotter MR, Li WW, Zhao C, Franklin RJ. Myelin 
impairs CNS remyelination by inhibiting oligo-
dendrocyte precursor cell differentiation. J Neu-
rosci. 2006;26(1):328–332.
 41. Wen H, et al. Fatty acid-induced NLRP3-ASC 
inflammasome activation interferes with insulin 
signaling. Nat Immunol. 2011;12(5):408–415.
 42. Schmidt H, et al. Type I interferon receptor sig-
nalling is induced during demyelination while its 
function for myelin damage and repair is redun-
dant. Exp Neurol. 2009;216(2):306–311.
Acknowledgments
P.L. Poliani is supported by Fondazione Cariplo. Y. Wang is sup-
ported by the Lilly Innovation Fellowship Award (Eli Lilly and 
Company). Y. Yamanishi is supported by a postdoctoral fellow-
ship for research abroad from the Japan Society for the Promo-
tion of Science. M. Colonna is supported by Knight Alzheimer’s 
Disease Research Center pilot grant P50 AG005681-30 and the 
Cure Alzheimer’s Fund. We thank the Genome Technology Access 
Center in the Department of Genetics (Washington University 
School of Medicine) for help with gene expression analysis. We 
thank Robert E. Schmidt, Karen Green, and the Morphology and 
Metabolic Analysis Core (Diabetes Research Center, Washing-
ton University School of Medicine, grant no. NIH DK020579) for 
assistance with TEM analyses. We thank Takashi Saito (RIKEN) 
for providing the NFAT-GFP reporter cells.
Address correspondence to: Marco Colonna, Washington Univer-
sity School of Medicine, Department of Pathology and Immunol-
ogy, 660 S. Euclid Ave., Box 8118, St. Louis, Missouri 63110, USA. 
Phone: 314.362.0367; E-mail: mcolonna@pathology.wustl.edu.
Downloaded from http://www.jci.org on October  9, 2015.   http://dx.doi.org/10.1172/JCI77983
The Journal of Clinical Investigation R e s e a R c h  a R t i c l e
2 1 7 0 jci.org   Volume 125   Number 5   May 2015
 43. Mason JL, Suzuki K, Chaplin DD, Matsushima 
GK. Interleukin-1β promotes repair of the CNS.  
J Neurosci. 2001;21(18):7046–7052.
 44. Olah M, et al. Identification of a microglia 
phenotype supportive of remyelination. Glia. 
2012;60(2):306–321.
 45. Voss EV, et al. Characterisation of microglia 
during de- and remyelination: can they create a 
repair promoting environment? Neurobiol Dis. 
2012;45(1):519–528.
 46. Otero K, et al. TREM2 and beta-catenin 
regulate bone homeostasis by controlling 
the rate of osteoclastogenesis. J Immunol. 
2012;188(6):2612–2621.
 47. Lingwood D, Simons K. Lipid rafts as a 
membrane-organizing principle. Science. 
2010;327(5961):46–50.
 48. Jonsson T, et al. Variant of TREM2 associated 
with the risk of Alzheimer’s disease. N Engl J Med. 
2013;368(2):107–116.
 49. Zhang B, et al. Integrated systems approach iden-
tifies genetic nodes and networks in late-onset 
Alzheimer’s disease. Cell. 2013;153(3):707–720.
 50. Cady J, et al. TREM2 variant p.R47H as a risk 
factor for sporadic amyotrophic lateral sclerosis. 
JAMA Neurol. 2014;71(4):449–453.
 51. Rayaprolu S, et al. TREM2 in neurodegeneration: 
evidence for association of the p.R47H variant 
with frontotemporal dementia and Parkinson’s 
disease. Mol Neurodegener. 2013;8:19.
 52. Wang Y, et al. TREM2 lipid sensing sustains the 
microglial response in an Alzheimer’s disease 
model. Cell. 2015;160(6):1061–1071.
 53. Wunderlich P, Glebov K, Kemmerling N, Tien 
NT, Neumann H, Walter J. Sequential proteolytic 
processing of the triggering receptor expressed 
on myeloid cells-2 (TREM2) protein by ectodo-
main shedding and gamma-secretase-dependent 
intramembranous cleavage. J Biol Chem. 
2013;288(46):33027–33036.
 54. Kleinberger G, et al. TREM2 mutations impli-
cated in neurodegeneration impair cell surface 
transport and phagocytosis. Sci Transl Med. 
2014;6(243):243ra286.
 55. Malik I, et al. Disrupted membrane homeostasis 
and accumulation of ubiquitinated proteins in a 
mouse model of infantile neuroaxonal dystro-
phy caused by PLA2G6 mutations. Am J Pathol. 
2008;172(2):406–416.
 56. Ohtsuka M, et al. NFAM1, an immunorecep-
tor tyrosine-based activation motif-bearing 
molecule that regulates B cell development 
and signaling. Proc Natl Acad Sci U S A. 
2004;101(21):8126–8131.
 57. Sedzik J, Blaurock AE. Myelin vesicles: what we 
know and what we do not know. J Neurosci Res. 
1995;41(2):145–152.
Downloaded from http://www.jci.org on October  9, 2015.   http://dx.doi.org/10.1172/JCI77983
